Spots Global Cancer Trial Database for bone marrow aspiration

Every month we try and update this database with for bone marrow aspiration cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	NCT06210750	T Acute Lymphob... T Lymphoblastic...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging	18 Years - 60 Years	National Cancer Institute (NCI)
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis	NCT01078337	Leukemia, Lymph...	bone marrow asp... peripheral bloo...	- 18 Years	Stanford University
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	NCT03878095	Malignant Solid... Refractory Chol... Refractory Mali...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	NCT06232044	Recurrent Multi... Refractory Mult...	Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Alliance for Clinical Trials in Oncology
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL	NCT03564704	Leukemia Leukemia, Acute Adult Lymphobla... Leukemia, Lymph... Leukemia, T Cel... Adult Acute Lym... Lymphoblastic L... Lymphoblastic L...	Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping Chidamide PET-CT scan	14 Years - 55 Years	Nanfang Hospital, Southern Medical University
Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma	NCT06042725	Multiple Myelom...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Chest Radiograp... Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Low Dose Comput... Magnetic Resona... Positron Emissi... Venetoclax X-Ray Imaging Questionnaire A...	18 Years -	Mayo Clinic
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention	NCT02423915	Leukemia Lymphoma	Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated...	18 Years - 80 Years	M.D. Anderson Cancer Center
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib	NCT00461929	Chronic Myeloid... Gastrointestina... Chromosome Abno...	bone marrow asp...	18 Years -	University Health Network, Toronto
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation	NCT04203316	Recurrent Acute... Refractory Acut...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy...	24 Months - 21 Years	Children's Oncology Group
CD155 Expression in Acute Myeloid Leukemia	NCT06369662	Acute Myeloid L...	Flow cytometric... Complete blood ... Bone marrow asp... Cytogenetic tes... FLT3-ITD using ...	18 Years - 60 Years	Assiut University
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	NCT03878095	Malignant Solid... Refractory Chol... Refractory Mali...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia	NCT04284787	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Azacitidine Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Pembrolizumab Venetoclax	60 Years -	National Cancer Institute (NCI)
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia	NCT02392429	Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Chemotherapy Computed Tomogr... Cytarabine Fluorothymidine... Laboratory Biom... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases	NCT04083183	Non-Malignant N...	Astatine At 211... Fludarabine Cyclophosphamid... Lapine T-Lympho... Total-Body Irra... Hematopoietic C... Mycophenolate M... Sirolimus Bone Marrow Asp... Biospecimen Col...	18 Years - 49 Years	Fred Hutchinson Cancer Center
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT05910801	Recurrent Mantl... Refractory Mant...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Lenalidomide Lumbar Puncture Magnetic Resona... Positron Emissi... Tafasitamab Venetoclax	18 Years -	Academic and Community Cancer Research United
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib	NCT00461929	Chronic Myeloid... Gastrointestina... Chromosome Abno...	bone marrow asp...	18 Years -	University Health Network, Toronto
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	NCT04764942	Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Mayo Clinic
Leukemia Cell Cultures for Research of New Anti-Cancer Therapies	NCT00993538	Acute Leukaemia	Blood sampling Bone marrow asp...	28 Days -	University Hospital, Strasbourg, France
Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer	NCT00826579	Colonic Neoplas...	Sentinel lymph ... Bone marrow asp...	-	University Hospital, Basel, Switzerland
Leukemia Cell Cultures for Research of New Anti-Cancer Therapies	NCT00993538	Acute Leukaemia	Blood sampling Bone marrow asp...	28 Days -	University Hospital, Strasbourg, France
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia	NCT01649791	B-cell Chronic ... Chronic Lymphoc... Stage 0 Chronic... Stage I Chronic... Stage II Chroni...	lenalidomide laboratory biom... lymph node biop... bone marrow asp... pharmacological... flow cytometry	18 Years -	Roswell Park Cancer Institute
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT05950113	Recurrent Multi... Refractory Mult...	Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Fludeoxyglucose... Immunotherapy Leukapheresis Magnetic Resona... Positron Emissi...	18 Years - 74 Years	Jonsson Comprehensive Cancer Center
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma	NCT04840602	Lymphoplasmacyt... Waldenstrom Mac...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Positron Emissi... Rituximab Venetoclax	18 Years -	National Cancer Institute (NCI)
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	NCT04359784	B-Cell Non-Hodg...	Anakinra X-Ray Imaging Positron Emissi... Computed Tomogr... Bone Marrow Asp... Bone Marrow Bio... Lumbar Puncture Biospecimen Col...	18 Years -	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia	NCT02003222	Acute Lymphobla... B Acute Lymphob...	Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging	30 Years - 70 Years	National Cancer Institute (NCI)
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome	NCT06287944	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an...	18 Years -	City of Hope Medical Center
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia	NCT04214249	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy	18 Years - 75 Years	National Cancer Institute (NCI)
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia	NCT01108497	Leukemia	Bone Marrow Asp...	- 18 Years	Stanford University
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia	NCT06311227	Recurrent Hairy... Recurrent Hairy...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Magnetic Resona... Venetoclax	18 Years -	National Cancer Institute (NCI)
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	NCT03418038	Clonal Cytopeni... High Grade B-Ce... Recurrent Diffu... Recurrent Hodgk... Recurrent Lymph... Refractory Diff... Refractory Lymp... Chronic Myelomo...	Ascorbic Acid Carboplatin Cisplatin Cytarabine Dexamethasone Etoposide Gemcitabine Hyd... Ifosfamide Laboratory Biom... Oxaliplatin Placebo Adminis... Questionnaire A... Rituximab Decitabine Biospecimen Col... Core Biopsy Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... Positron Emissi... Magnetic Resona... Central Venous ... Portacath Place... Computed Tomogr...	18 Years -	Mayo Clinic
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma	NCT00621452	B-cell Chronic ... Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	therapeutic aut... cyclophosphamid... aldesleukin polymerase chai... gene rearrangem... lymph node biop... genetically eng... bone marrow asp... flow cytometry laboratory biom... enzyme-linked i...	-	Fred Hutchinson Cancer Center
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	NCT05455697	Diffuse Large B... Grade 3b Follic... High Grade B-Ce...	Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved...	18 Years -	University of Washington
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia	NCT02003222	Acute Lymphobla... B Acute Lymphob...	Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging	30 Years - 70 Years	National Cancer Institute (NCI)
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	NCT04751383	High Risk Neuro... Recurrent Neuro... Recurrent Osteo... Refractory Neur... Resectable Oste...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab Magnetic Resona... Magrolimab Resection	2 Years - 35 Years	National Cancer Institute (NCI)
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer	NCT02849496	Anatomic Stage ... Anatomic Stage ... Locally Advance... Locally Advance... Metastatic Brea... Metastatic HER2... Unresectable Br... Unresectable HE...	Atezolizumab Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bone Scan Computed Tomogr... Magnetic Resona... Olaparib Positron Emissi... Questionnaire A... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention	NCT02423915	Leukemia Lymphoma	Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated...	18 Years - 80 Years	M.D. Anderson Cancer Center
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial	NCT04764942	Recurrent Multi... Refractory Mult...	Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Mayo Clinic
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	NCT04375631	Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut...	Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp...	18 Years -	Fred Hutchinson Cancer Center
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL	NCT03553238	Leukemia, Acute Leukemia, T Cel... Leukemia, Lymph...	Chidamide Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-Mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping	14 Years - 55 Years	Nanfang Hospital, Southern Medical University
Leukemia Cell Cultures for Research of New Anti-Cancer Therapies	NCT00993538	Acute Leukaemia	Blood sampling Bone marrow asp...	28 Days -	University Hospital, Strasbourg, France
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL	NCT03553238	Leukemia, Acute Leukemia, T Cel... Leukemia, Lymph...	Chidamide Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-Mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping	14 Years - 55 Years	Nanfang Hospital, Southern Medical University
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene	NCT05886049	Acute Myeloid L... Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E...	18 Years - 75 Years	National Cancer Institute (NCI)
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia	NCT01108497	Leukemia	Bone Marrow Asp...	- 18 Years	Stanford University
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma	NCT04892264	Plasma Cell Mye... Recurrent Plasm... Refractory Plas...	Belantamab Mafo... Daratumumab Dexamethasone Lenalidomide Quality-of-Life... Biospecimen Col... Skeletal Survey... Low Dose Comput... Bone Marrow Asp... Bone Marrow Bio...	18 Years -	Mayo Clinic
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome	NCT05457556	Acute Lymphobla... Acute Myeloid L... Mixed Phenotype... Myelodysplastic...	Biospecimen Col... Bone Marrow Asp... Busulfan Cyclophosphamid... Echocardiograph... Fludarabine Haploidentical ... Lapine T-Lympho... Lumbar Puncture Matched Unrelat... Melphalan Methotrexate Multigated Acqu... Mycophenolate M... Myeloablative C... Quality-of-Life... Questionnaire A... Rituximab T-Cell Depletio... Tacrolimus Thiotepa Total-Body Irra...	6 Months - 21 Years	Children's Oncology Group
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation	NCT04203316	Recurrent Acute... Refractory Acut...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy...	24 Months - 21 Years	Children's Oncology Group
A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia	NCT00601991	Leukemia	VEGF Trap Bone marrow bio... bone marrow asp... Venipuncture	18 Years -	Vanderbilt-Ingram Cancer Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	NCT01955499	Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Lenalidomide Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study	NCT04269902	Chronic Lymphoc... Small Lymphocyt...	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Obinutuzumab Quality-of-Life... Questionnaire A... Venetoclax	18 Years -	National Cancer Institute (NCI)
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)	NCT04385277	Ganglioneurobla... Neuroblastoma	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab FDG-Positron Em... Iobenguane I-12... Irinotecan Isotretinoin Magnetic Resona... Multigated Acqu... Sargramostim Temozolomide	- 30 Years	Children's Oncology Group
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	NCT05981209	Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dexamethasone Echocardiograph... Elotuzumab Magnetic Resona... Mezigdomide X-Ray Imaging	18 Years -	Ohio State University Comprehensive Cancer Center
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)	NCT04965597	Bone Marrow Fai... Congenital Ameg... Congenital Pure... Hereditary Side... Paroxysmal Noct... Shwachman-Diamo... Hematologic Neo... Hematologic Neo... Hematologic Neo...	Treosulfan Fludarabine Pho... Tacrolimus Methotrexate Lapine T-Lympho... Peripheral Bloo... Allogeneic Bone... Quality-of-Life... Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	1 Year - 49 Years	Fred Hutchinson Cancer Center
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation	NCT03953898	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel...	Biospecimen Col... Bone Marrow Asp... Olaparib	18 Years -	National Cancer Institute (NCI)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)	NCT06317649	Acute Myeloid L...	Azacitidine Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Gilteritinib Venetoclax	18 Years -	National Cancer Institute (NCI)
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia	NCT02392429	Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Chemotherapy Computed Tomogr... Cytarabine Fluorothymidine... Laboratory Biom... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia	NCT04007081	Xerostomia Head and Neck C...	Bone Marrow Asp... Ultrasound Imag... Salivary Assay Quality of Life...	18 Years - 89 Years	University of Wisconsin, Madison
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01342887	Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult...	cyclosporine pravastatin sod... mitoxantrone hy... etoposide bone marrow asp...	18 Years -	Fred Hutchinson Cancer Center
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma	NCT06179888	Multiple Myelom...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Iberdomide Magnetic Resona... Patient Monitor... Positron Emissi... Skeletal Survey...	18 Years -	National Cancer Institute (NCI)
Role of PTK-7 in Acute Myeloid Leukemias	NCT02860793	Acute Myeloid L...	Bone marrow asp... Blood sampling	18 Years -	Institut Paoli-Calmettes
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy	NCT03959085	B Acute Lymphob... B Lymphoblastic... Central Nervous... Mixed Phenotype... Testicular Leuk...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bone Scan Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Leucovorin Calc... Magnetic Resona... Mercaptopurine Methotrexate Pegaspargase Positron Emissi... Prednisolone Questionnaire A... Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul...	1 Year - 25 Years	Children's Oncology Group
Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia	NCT04007081	Xerostomia Head and Neck C...	Bone Marrow Asp... Ultrasound Imag... Salivary Assay Quality of Life...	18 Years - 89 Years	University of Wisconsin, Madison
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia	NCT01093573	Untreated Adult...	midostaurin azacitidine bone marrow asp... mutation analys... Pharmacokinetic...	-	Case Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene	NCT05886049	Acute Myeloid L... Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E...	18 Years - 75 Years	National Cancer Institute (NCI)
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	NCT06232044	Recurrent Multi... Refractory Mult...	Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Alliance for Clinical Trials in Oncology
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma	NCT01155583	Refractory Mult...	azacitidine lenalidomide dexamethasone DNA methylation... gene expression... bone marrow asp... immunohistochem... reverse transcr... flow cytometry	18 Years -	Case Comprehensive Cancer Center
Role of PTK-7 in Acute Myeloid Leukemias	NCT02860793	Acute Myeloid L...	Bone marrow asp... Blood sampling	18 Years -	Institut Paoli-Calmettes
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma	NCT02176967	Ganglioneurobla... Localized Resec... Localized Unres... Neuroblastoma	Biopsy Bone Marrow Asp... Bone Marrow Bio... Carboplatin Clinical Observ... Computed Tomogr... Cyclophosphamid... Doxorubicin Hyd... Etoposide Magnetic Resona... Ultrasound	- 18 Months	Children's Oncology Group
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib	NCT00461929	Chronic Myeloid... Gastrointestina... Chromosome Abno...	bone marrow asp...	18 Years -	University Health Network, Toronto
Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia	NCT04007081	Xerostomia Head and Neck C...	Bone Marrow Asp... Ultrasound Imag... Salivary Assay Quality of Life...	18 Years - 89 Years	University of Wisconsin, Madison

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: